流感季来袭！奥司他韦卖爆，流感药物备货能否跟上？

Core Insights - The current flu season in 2025 is marked by a significant increase in flu cases, with a 237% year-on-year surge in the sales of Oseltamivir and a 180% increase for the novel antiviral drug Marbofloxacin [1][2] - The predominant strain this year is the H3N2 subtype, which has replaced last year's H1N1, indicating a regular antigenic drift rather than a more dangerous mutation [1] - Flu differs significantly from the common cold, with flu symptoms being more severe and potentially leading to serious complications such as myocarditis, encephalitis, and pneumonia [2] Prevention and Treatment - Vaccination is emphasized as the primary preventive measure, with recommendations for all individuals over 6 months old to receive the flu vaccine, especially vulnerable groups such as the elderly, chronic disease patients, pregnant women, young children, and healthcare workers [2] - This year, 10 manufacturers have approved flu vaccines in China, with prices ranging from 31 to 103 yuan per dose, making them more accessible [2] - In case of infection, it is crucial to use antiviral medications like Oseltamivir or Marbofloxacin within 48 hours of symptom onset for effective treatment [2][3] Supply and Availability - The original manufacturer of Marbofloxacin, Roche, has localized production in Shanghai, increasing the supply to over three times that of last year, ensuring availability in hospitals nationwide [3] - An emergency supply mechanism is in place to address potential outbreaks in specific regions [3]